Genflow Biosciences (LSE:GENF; OTCQB:GENFF) has announced the signing of a master service agreement (MSA) with closely held CER Groupe—a long-standing partner—to strengthen long-term research and development (R&D) collaboration.
According to Genflow, the terms of the MSA will develop, produce, and characterize its gene therapy candidates, implement a collaborative project management system, and the combine scientific expertise derisks, innovate, and ensure relevant scientific outcomes.
Dr. Eric Leire, CEO of Genflow, commented, “Our partnership with CER has been instrumental in supporting our R&D efforts to date. Formalizing this collaboration through the MSA will enable greater operational alignment and strategic agility as we continue to accelerate our pipeline.”
